


CLAIMS

- 1 . Use of P-CABs in the treatment of sleep disturbance due to silent gastro-esophageal reflux.
5
2. Use of P-CABs for the treatment of patients who are suffering from sleep disturbance due to silent gastro-esophageal reflux.
3. Method for the treatment of sleep disturbance due to silent gastro-esophageal reflux
10 consisting in that an effective amount of a P-CAB is administered to a patient who needs such a treatment.
4. Use of P-CABs for the production of medicaments for the treatment of sleep disturbance due to silent gastro-esophageal reflux.
15
5. Pharmaceutical preparation for the treatment of sleep disturbance due to silent gastro-esophageal reflux, containing a P-CAB as active compound together with a pharmaceutically acceptabler diluent or carrier.
- 20 6. Pharmaceuticle preparation according to claim 5 suitable for immediate-release.
7. Pharmaceutical preparation according to claim 5 suitable for modified release.
8. P-CAB as mentioned in anyone of claims 1 – 7 , wherein the P-CAB compound is a
25 compound of Formula I



I

or a pharmaceutically acceptable salt thereof, and

R¹ is

5

- (a) H,
- (b) CH₃, or
- (c) CH₂OH;

R² is

10

- (a) CH₃
- (b) CH₂CH₃

R³ is

15

- (a) H
- (b) C₁-C₆ alkyl,
- (c) hydroxylated C₁-C₆ alkyl
- (d) halogen

R⁴ is

20

- (a) H,
- (b) C₁-C₆ alkyl,
- (c) hydroxylated C₁-C₆ alkyl, or
- (d) halogen;

R⁵ is

25

- (a) H, or

(b) halogen;

R^6, R^7 are the same or different

(a) H,

(b) C_1-C_6 alkyl;

(c) hydroxylated C_1-C_6 alkyl

(d) C_1-C_6 alkoxy-substituted C_1-C_6 alkyl

X is

(a) NH, or

(b) O;

or pharmaceutically acceptable salt thereof.

9. P-CAB as mentioned in anyone of claims 1 – 7, wherein the P-CAB compound is a compound of Formula I and R^1 is CH_3 or CH_2OH ; R^2, R^3 and R^4 independently are CH_3 or CH_2CH_3 ; R^5 is H, Br, Cl, or F and R^6, R^7 are the same or different and chosen from a group consisting of H, C_1-C_6 alkyl, and hydroxylated C_1-C_6 alkyl; or a pharmaceutically acceptable salt thereof.

10. P-CAB as mentioned in anyone of claims 1 – 7, wherein the P-CAB compound is a compound selected from a group consisting of 8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2,6-dimethyl-4-fluoro-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2,6-diethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,
2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-hydroxyethyl-imidazo[1,2-
a]pyridine-6-carboxamide, and

2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-(2-methoxyethyl)-imidazo[1,2-
a]pyridine-6-carboxamide,

or a pharmacologically acceptable salt thereof.

11. P-CAB as mentioned in anyone of claims 1 – 7, wherein the P-CAB compound is in
the form of hydrochloride or mesylate salt.

12. Use of reversible proton pump inhibitors in the treatment of sleep disturbance due to
silent gastro-esophageal reflux.

13. Use of reversible proton pump inhibitors for the treatment of patients who are suffering
from sleep disturbance due to silent gastro-esophageal reflux.

14. Method for the treatment of sleep disturbance due to silent gastro-esophageal reflux
consisting in that an effective amount of a reversible proton pump inhibitors is
administered to a patient who needs such a treatment.

15. Use of reversible proton pump inhibitors for the production of medicaments for the
treatment of sleep disturbance due to silent gastro-esophageal reflux.

16. Pharmaceutical preparation for the treatment of sleep disturbance due to silent gastro-
esophageal reflux, containing a reversible proton pump inhibitors as active compound
together with a pharmaceutically acceptable diluent or carrier.

17. Pharmaceuticle preparation according to claim 16 suitable for immediate-release.

18. Pharmaceutical preparation according to claim 16 suitable for modified release.

19. Reversible proton pump inhibitor as mentioned in claims 12-18, characterized in that it is soraprazan